Bezafibrate is a PPAR? agonist that is clinically used to lower LDL and triglyceride levels and to increase HDL levels. Bezafibrate exhibits anti-hyperlipidemic, cardioprotective, anti-diabetic, anti-osteoporotic, and anticancer chemotherapeutic activities. When administered clinically, bezafibrate decreases risk of myocardial infarction and cardiac mortality; it also decreases the incidence and delays the onset of type 2 diabetes. Bezafibrate promotes bone formation by activating proliferation and differentiation of osteoblasts in vitro in an AMPK- and PPAR?-dependent manner. In animal models of non-small cell lung cancer (NSCLC), bezafibrate decreases angiogenesis and tumor growth through downregulation of Cyp2c expression or activity.
Popular test
Uniformity of Dosage Units
Allschoolabs
Uniformity of Dosage Units is a specialised analytical laboratory service that assesses whether individual dosage units contain sufficiently consis...
![ANTI D TITRE – [Serum]](https://app.analysisafrica.com/backend/uploads/tests/images/1754385122_6891cae238432.jpg)
No products in the cart.